Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays

Abstract

Purpose: Prognosis for patients with glioblastoma (GBM) remains poor, and new treatments are needed. Here we used a combination of two novel treatment modalities: Carbon ions and a histone deacetylase inhibitor (HDACi). We compared these to conventional X-rays, measuring the increased effectiveness of carbon ions as well as radiosensitization using HDACi.

Materials and methods: Suberoylanilide hydroxamic acid (SAHA) was used at a non-toxic concentration of 0.5 μM in combination with 85 keV μm⁻¹ carbon ions, and 250 kVp X-rays for comparison. Effects were assayed using clonogenic survival, γH2AX foci repair kinetics and measuring chromatin decondensation.

Results: Dose toxicity curves showed that human GBM LN18 cells were more sensitive to SAHA compared to U251 cells at higher doses, but there was little effect at low doses. When combined with radiation, clonogenic assays showed that the Sensitizer Enhancement Ratio with carbon ions at 50% survival (SER₅₀) was about 1.2 and 1.5 for LN18 and U251, respectively, but was similar for X-rays at about 1.3. The repair half-life of γH2AX foci was slower for cells treated with SAHA and was most noticeable in U251 cells treated with carbon ions where after 24 h, more than double the number of foci remained in comparison to the untreated cells. Hoechst fluorescent dye incorporation into the nucleus showed significant chromatin decondensation and density homogenization with SAHA treatment for both cell lines.

Conclusion: Our results suggest a vital role of histone deacetylases (HDAC) in the modulation of DNA damage response and support the use of SAHA for the treatment of GBM through the combination with heavy ion therapy.

Keywords::

• High-LET
• clonogenic assay
• chromatin decondensation
• DNA double-strand break repair

Acknowledgements

This work has been supported by the European Community as an Integrating Activity “Support of Public and Industrial Research Using Ion Beam Technology (SPIRIT)” under EC contract no. 227012, by SPRITE, and by the UK EPSRC under grant EP/C009592/1. LB has received funding from the European Community's Seventh Framework Programme (FP7/2007–2013 under grant agreement no. 215840-2). ACW is supported by Marie Curie Actions – Initial Training Networks (ITN) as an Integrating Activity Supporting Postgraduate Research with Internships in Industry and Training Excellence (SPRITE) under EC contract no. 317169. We also acknowledge HIMAC (Japan) for granting beamtime to perform the experiments, as well as Royal Surrey County Hospital UK) for providing beamtime for the X-ray experiments.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Supplementary material available online

Supplementary Figure 1 available online at http://informahealthcare.com/abs/doi/10.3109/09553002.2014.946111